On Friday, Honeywell International Inc. (NYSE:HON)’s shares inclined 0.07% to $99.62.
If ketchup in a squeezable bottle was the last food packaging revolution, could spray able ketchup be the next one? It could be, according to a new survey commissioned by Honeywell (HON) that looked at consumer attitudes toward aerosols and what applications they would like to see in the future. The survey of more than 1,000 U.S. adults found that two-thirds (66 percent) would use some type of food and household product if it were accessible as an aerosol.
The most popular among food items? Spray-on chocolate (11 percent), followed by spray-on salt (9 percent) and spray-on ketchup (8 percent). Demand for spray-on chocolate in households with children nearly doubles when contrast to those with no children. The survey also found that the vast majority of consumers (93 percent) use aerosol products in some capacity, and that the perception of aerosols being harmful to the environment is fading.
Honeywell International Inc. operates as a diversified technology and manufacturing company worldwide. Its Aerospace segment provides aircraft engines, integrated avionics, systems and service solutions, and related products and services for aircraft manufacturers and operators, airlines, military services, and defense and space contractors; and spare parts, and repair and maintenance services for the aftermarket. This segment provides auxiliary power units; propulsion engines; turbochargers and thermal systems; engine controls; environmental control, electric power, flight safety, communications, navigation, radar, and surveillance systems; aircraft lighting; systems and instruments; aircraft wheels and brakes; and administration, technical, logistics, repair, and overhaul services for original equipment manufacturers in the air transport, regional, business, and general aviation aircraft, in addition to for automotive and truck manufacturers.
ARM Holdings plc (ADR) (NASDAQ:ARMH)’s shares dropped -0.98% to $43.60.
ARM has partnered with Thundersoft, a world leader in smart device platforms, to establish the ARM Innovation Ecosystem Accelerator. The partnershipcreates an Internet of Things (IoT) one-stop shop for startups and established OEMs, providing integrated hardware and software expertise in addition to resources from the ARM® ecosystem. The Beijing facility is the first of four planned and is aimed at further advancing China’s IoT industry.
The first office in Zhongguancun, Beijing, will offer an ARM mbed™ IoT Device Platform innovation lab and an ARM Cortex®-based IoT system on chip (SoC) design lab alongside joint facilities with ecosystem partners. The accelerator will provide operateshops, training, and design services for mbed OS and Cortexprocessor-based development platforms. System integration services aligned to the needs of the local design environment will also be accessible to further facilitate and speed up the path from prototype to production.
ARM Holdings plc, together with its auxiliaries, designs microprocessors, physical intellectual property (IP), and related technology and software. The company also sells development tools that enhance the performance of embedded applications. Its products comprise microprocessor cores that comprise of specific functions, such as video, graphics, and display technology IP; and physical IP components for the design and manufacture of integrated circuits, which comprise embedded memory, standard cell, and input/output components.
At the end of Friday’s trade, Goldman Sachs Group Inc (NYSE:GS)‘s shares dipped -0.41% to $185.14.
Recently, Goldman Sachs Asset Administration (“GSAM”) declared the launch of the Goldman Sachs Absolute Return Multi-Asset Fund (Class A Shares: GARDX) (“The Fund”), which seeks to generate comprising, attractive returns that are less dependent on the direction of traditional markets. The Fund invests across multiple asset classes accessing investment ideas from across GSAM with a dynamic asset allocation approach to navigate changing markets.
The Fund is managed by GSAM’s Global Portfolio Solutions group, the dedicated multi-asset investing team within the division. The team, which comprises of over 95 professionals around the globe, has offered multi-asset class investment solutions to clients for more than 20 years and presently manages over $35 billion.2
The Goldman Sachs Group, Inc. operates as an investment banking, securities, and investment administration company worldwide. The company operates through four segments: Investment Banking, Institutional Client Services, Investing & Lending, and Investment Administration. The Investment Banking segment provides financial advisory services, such as planned advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, spin-offs, and risk administration; and underwriting services, counting public offerings and private placements of a range of securities and other financial instruments, in addition to derivative transactions reached with public and private sector clients.
Incyte Corporation (NASDAQ:INCY), ended its Friday’s trading session with 5.23% gain, and closed at $131.01.
Aduro Biotech, Inc. (ADRO) declared recently that it has reached a clinical trial agreement with Incyte Corporation (INCY) to evaluate the safety, tolerability and preliminary efficacy of Aduro’s lead LADD immunotherapy, CRS-207, in combination with Incyte’s oral indoleamine dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), in patients with ovarian cancer.
The combination of both investigational immunotherapeutic agents, which have different but complementary mechanisms directed at enhancing the body’s own immune defenses, may provide unique synergies in fighting cancer. Incyte’s epacadostat has been shown in vitro and in preclinical tumor models to enhance activities of multiple types of immune cells by reducing the immune suppression characteristic of the tumor microenvironment. Aduro’s CRS-207 has been shown to stimulate immune cell activity, with particular targeting mechanisms that seek and attack tumor cells that express mesothelin like those found in ovarian cancer.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), counting primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line comprises ruxolitinib, which is in Phase III clinical trial for pancreatic cancer; and in Phase II trial for the treatment of breast cancer, non-small cell lung cancer, and colorectal cancer, in addition to INCB39110 that is in Phase I/II trial for malignancies; and in Phase II trial for non-small cell lung cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
